Proteins that control retinal repair after damage

Characterization of the nascent retinal proteome regulating Hippo signaling during damage

NIH-funded research Baylor College of Medicine · NIH-11145216

This project looks at newly made proteins that switch on a growth-control pathway in damaged retinas to help guide future therapies for people with conditions like age-related macular degeneration and glaucoma.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionBaylor College of Medicine NIH-funded
Lab location1 site (Houston, United States)
Project IDNIH-11145216 on NIH RePORTER

What this research studies

From a patient perspective, researchers will compare how support cells in damaged zebrafish and mouse retinas make new proteins after injury. They will focus on Müller glia and use biochemical proteomics to capture and identify proteins that activate the Hippo/YAP signaling pathway. By finding the upstream protein triggers that differ between regenerative fish and non-regenerative mammals, the team hopes to reveal targets that could be turned into treatments to promote retinal neuron regrowth. This work is lab-based and uses animal models to build evidence for therapies that might later be tested in people.

Who could benefit from this research

Good fit: People with retinal degenerative conditions such as age-related macular degeneration, glaucoma, or those who have suffered retinal injury would be the likely future candidates for therapies informed by this work.

Not a fit: Patients whose vision loss is caused by non-retinal problems or by extensive scarring and irreversible tissue loss may not benefit from approaches that aim to regrow retinal neurons.

Why it matters

Potential benefit: If successful, the findings could point to new ways to stimulate retinal support cells to regrow neurons and potentially restore vision in people with retinal degeneration.

How similar studies have performed: Zebrafish reliably regenerate retinal neurons and early mouse experiments manipulating Hippo/YAP show limited reprogramming, but translating these findings into human therapies remains unproven.

Where this research is happening

Houston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.